A regimen of selinexor and bortezomib once weekly combined with twice-weekly dexamethasone is an effective and convenient option for previously treated patients with multiple myeloma (MM), according to results reported in the Lancet.
In the ongoing, open-label, phase 3 Boston (Bortezomib, Selinexor and Dexamethasone) trial (ClinicalTri-als.gov Identifier: NCT03110562), investigators at 123 sites in 21 countries randomly assigned 402 patients in a 1:1 fashion to receive selinexor (Xpovio,